Wave Life Sciences Ltd.

Wave Life Sciences Ltd. is a Singapore-incorporated biotechnology company with operating subsidiaries in the United States, Japan, Ireland, and the United Kingdom. It develops oligonucleotide-based medicines designed to modulate RNA for genetic and other diseases, with programs spanning preclinical and clinical-stage therapeutic candidates.

317

6.47

6.35

— Wave Life Sciences Ltd.
%
Clinical-stage therapeutic programs0% Drug candidates in human testing, including programs for genetic and metabolic diseases.
Preclinical discovery programs0% Earlier-stage RNA medicines being designed and tested before clinical development.
Collaboration revenue100% Revenue recognized from partnered research and development agreements.

Wave does not currently sell approved products; its economic counterparties are collaboration partners that fund or...

  • Strategic collaboration partnersprimary

    Pharma partners that pay for or co-fund discovery and development work under collaboration agreements.

  • Future specialty prescriberssecondary

    Physicians who would prescribe approved therapies in rare disease or metabolic settings.

  • Future patientssecondary

    Patients with genetic or metabolic diseases who would receive approved RNA medicines.

Wave is incorporated in Singapore but maintains principal operating presence in Cambridge, Massachusetts, with...

  • •Singapore is the legal domicile and registered office location
  • •Cambridge, Massachusetts is the principal U.S. operating base
  • •Japan, Ireland, and the UK house wholly owned subsidiaries
  • •Business is research-driven and not tied to product sales geography

Wave’s strategy centers on advancing RNA medicines through internal discovery and clinical development while using...

01
Advance lead therapeutic programsshort-term

Clinical progress is the main path to value creation in a pre-commercial biotech model.

02
Maintain and expand collaborationsmedium-term

Partnering helps fund development and can accelerate translation of programs.

03
Strengthen scientific and IP positionlong-term

Differentiated RNA chemistry and protected know-how are central to competition.

Wave is a clinical-stage biotechnology company with no approved product sales, so its business depends on successful...

high

Clinical-stage development risk

Product candidates may not demonstrate safety or efficacy in trials, which can halt development.

Scope
Lead programs in genetic and metabolic disease
Materiality
high
high

Dependence on collaboration agreements

A meaningful portion of revenue comes from partner-funded work and can fluctuate with contract terms.

Scope
GSK and Takeda collaborations
Materiality
high
medium

No commercial infrastructure

The company has no sales, marketing, or distribution capabilities for approved products.

Scope
Future commercialization
Materiality
high
medium

Competition for talent and capital

Biotech development requires specialized scientists, trial sites, and funding in a crowded market.

Scope
R&D organization and pipeline execution
Materiality
medium
medium

Third-party manufacturing and trial execution

CROs and CMOs are needed for preclinical and clinical work, creating operational dependency.

Scope
Drug substance and clinical supply chain
Materiality
medium
Collaboration revenue recognition
Affects reported collaboration revenue and quarterly comparability
CRO and CMO accrual estimates
Affects R&D expense and operating loss
Share-based compensation
Affects G&A and R&D expense levels
Lease accounting
Affects balance sheet liabilities and cash flow planning

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

LISATA THERAPEUTICS, INC.

LSTA · Pharmaceutical Preparations

SELLAS Life Sciences Group, Inc.

SLS · Pharmaceutical Preparations

Korro Bio, Inc.

KRRO · Pharmaceutical Preparations

Generation Bio Co.

Pharmaceutical Preparations

: 29/04/2026